Platelet-Derived Growth Factors Market Revenue to Attain USD 2.95 Bn by 2033

05 Aug 2025

Share :

Table of Content

1. Platelet-Derived Growth Factors Market Revenue and Trends 2025 to 2033 2. Unlocking the Potential: A Strategic Look at the Platelet-Derived Growth Factors Market 3. Segment Insights 4. Regional Insights 5. Platelet-Derived Growth Factors Market Coverage 6. Platelet-derived Growth Factors Market Key Players

Platelet-Derived Growth Factors Market Revenue and Trends 2025 to 2033

The global platelet-derived growth factors market revenue reached USD 1.42 billion in 2025 and is predicted to attain around USD 2.95 billion by 2033 with a CAGR of 9.54%. This market is growing due to the increasing demand for regenerative medicine and wound healing therapies. Advancements in biotechnology and a growing aging population further contribute to the growth of the market.

Unlocking the Potential: A Strategic Look at the Platelet-Derived Growth Factors Market

The market for platelet-derived growth factors is experiencing substantial growth, fueled by a variety of factors. Firstly, the rising incidence of chronic wounds, orthopedic injuries, and cardiovascular diseases is increasing the demand for regenerative therapeutics. PDGF's demonstrated ability to promote cellular proliferation, angiogenesis, and tissue repair further validates its use in treating chronic wound healing and post-surgical recovery. Secondly, increased awareness and the adoption of biologics in healthcare initiatives, alongside broader applications in low-risk dermatology and cosmetic procedures, support the advancement of PDGF products.

Additional factors include research initiatives utilizing PDGF in regenerative medicine and the development of new PDGF therapeutics, driven by advances in biotechnology, which are associated with commercialization and increased R&D investments from the pharmaceutical industry. Favorable regulatory pathways promoting PDGF products and technological advancements in regenerative medicine create immense opportunities in the market.

Segment Insights

• By product type, the recombinant human PDGF segment held the largest share of the market in 2024, as it demonstrated success in promoting tissue regeneration. There is a high demand for recombinant human PDGFs due to their proven effectiveness in regenerative therapies and wound healing.
• By application, the wound healing & ulcer treatment segment dominated the market in 2024. This is mainly due to the proven effectiveness of PDGF in wound healing. With the rising number of cases of diabetic foot ulcer, the demand for PDGF is rising in wound healing therapies.
• By end-user, the hospitals & clinics segment contributed the largest share of the market in 2024 due to the increased patient pool in these settings. The easy availability of regenerative therapies and wound healing therapies in these settings, along with the advanced healthcare infrastructure and dedicated staff, attracts more patients.
• By route of administration, the injectable segment dominated the market in 2024 due to the increased demand for targeted therapies. Because it can be quickly absorbed, provides site-specific delivery, and offers enhanced effectiveness in a regenerative approach, there is a high preference for injectables.
• By formulation, the gel/hydrogel formulations segment dominated the market in 2024 due to their ability to provide greater healing efficiency. They stay on the wound site for a longer time, providing moist and promoting rapid healing.

Regional Insights

North America registered dominance in the platelet-derived growth factors market in 2024 due to improved healthcare infrastructure and high adoption of regenerative therapies. The presence of major biopharmaceutical companies and the rising demand for cosmetic procedures further facilitate the market growth in the region.

Asia Pacific is expected to experience the fastest growth in the market due to the increasing healthcare expenditures and the rising incidence of chronic wounds. As a result, there is a rising demand for biologic therapies. Moreover, the growing number of cases of injuries is boosting the demand for wound healing treatments, which is likely to support regional market growth.

Platelet-Derived Growth Factors Market Coverage

Recent Development

• On April 29, 2024, Bio Techne announced a strategic European distribution agreement with Thermo Fisher Scientific, effective May 1, 2024, to expand access across Europe to its portfolio, including recombinant proteins relevant to PDGF research.
  (Source: https://instrumentbusinessoutlook.com)

Platelet-derived Growth Factors Market Key Players

• Smith & Nephew plc
• Zimmer Biomet Holdings Inc.
• Stryker Corporation
• Johnson & Johnson (DePuy Synthes)
• Medtronic plc
• Anika Therapeutics
• BioD LLC (part of Integra LifeSciences)
• Platelet BioGenesis
• Grifols S.A.
• Entegrion Inc.
• Thermo Fisher Scientific Inc.
• R&D Systems (Bio-Techne)
• BioWorks, Inc.
• Revmedx Inc.
• Orthocell Ltd.
• EmCyte Corporation
• Regen Lab SA
• APEX Biologix
• Terumo BCT
• TBF Genie

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6522

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344